Hello, Fool! | Login | Signup | My Fool
Jan 9, 2009 10:10 PM ET | Feedback | Site Changes | Help
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
View All Commentary (ENMD)
Recs
dwr53 (< 20) Submitted: 4/25/07 8:28 PM : Start Price: $1.79 ENMD Score: -46.75
They have several phase two cancer candidates. Approximately 25% of the shares are owned by Celgene. I suspect they will be taken out by a big pharma looking to improve their pipeline.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK